Merck Adds 10 Studies To ClinicalTrials.gov, Bringing Total To 13
This article was originally published in The Pink Sheet Daily
The 10 new Merck entries include three Phase III studies in type 2 diabetes. The company's listings are still relatively few when compared to its peers.
You may also be interested in...
Merck says it prefers to continue to fly below the radar screen with respect to ClinicalTrials.gov unless the law is changed. Merck's response to AMA's clinical trials registry proposal receives national media attention, but the company is an unlikely champion for government-sponsored public trial databases.
All trials should be registered to ensure results are publicly available, physicians’ association says. Institutional review boards should not approve trials unless they are registered, AMA policy urges.
ClinROs, artificial intelligence-based algorithms will be included in approval pathway. FDA is taking a crash course on new techniques for trial assessment thanks to COVID.